// App-Quantinova.ai

e16094 : Sensitive and dynamic CTCs measurement for prediction and monitoring of PD-1 therapy in GC/EGJC patients: Results from a pilot phase 2 study.

Researchers

Presenter

  • Qing Wei

Principal Investigators

  • Xu Qi

  • Lei Chen

  • Yanlian Yang

  • Yankun Li

  • Zhiyuan Hu

  • Jieer Ying

  • Cong Luo

  • Li Jingjing

Medical Centers

  • Department of Breast Surgery, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital; Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Hangzhou, China

  • Nanopep Biotech Co., Beijing, China

  • Department of Breast Surgery, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital; Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Hangzhou, China

  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou/CN

  • Department of Breast Surgery, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital; Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Hangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • Circulating tumor cells

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • Apatinib

  • JS001

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04190745

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved